These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

328 related items for PubMed ID: 21519359

  • 21. Randomised double blind placebo controlled trial investigating the effect of calcium and vitamin D supplementation on bone mineral density and bone metabolism in adult patients with cystic fibrosis.
    Haworth CS, Jones AM, Adams JE, Selby PL, Webb AK.
    J Cyst Fibros; 2004 Dec; 3(4):233-6. PubMed ID: 15698940
    [Abstract] [Full Text] [Related]

  • 22. A double blind study of intranasal calcitonin for established postmenopausal osteoporosis.
    Kapetanos G, Symeonides PP, Dimitriou C, Karakatsanis K, Potoupnis M.
    Acta Orthop Scand Suppl; 1997 Oct; 275():108-11. PubMed ID: 9385282
    [Abstract] [Full Text] [Related]

  • 23. Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease.
    Stokkers PC, Deley M, Van Der Spek M, Verberne HJ, Van Deventer SJ, Hommes DW.
    Scand J Gastroenterol; 2006 Feb; 41(2):200-4. PubMed ID: 16484125
    [Abstract] [Full Text] [Related]

  • 24. Treatment of postmenopausal osteoporosis with continuous daily oral alendronate in comparison with either placebo or intranasal salmon calcitonin.
    Adami S, Baroni MC, Broggini M, Carratelli L, Caruso I, Gnessi L, Laurenzi M, Lombardi A, Norbiato G, Ortolani S.
    Osteoporos Int; 1993 Feb; 3 Suppl 3():S21-7. PubMed ID: 8298199
    [Abstract] [Full Text] [Related]

  • 25. A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study.
    Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium.
    Eur Urol; 2013 May; 63(5):927-35. PubMed ID: 23040208
    [Abstract] [Full Text] [Related]

  • 26. Treatment of bone loss in osteopenic patients with Crohn's disease: a double-blind, randomised trial of oral risedronate 35 mg once weekly or placebo, concomitant with calcium and vitamin D supplementation.
    van Bodegraven AA, Bravenboer N, Witte BI, Dijkstra G, van der Woude CJ, Stokkers PC, Russel MG, Oldenburg B, Pierik M, Roos JC, van Hogezand RA, Dik VK, Oostlander AE, Netelenbos JC, van de Langerijt L, Hommes DW, Lips P, Dutch Initiative on Crohn and Colitis (ICC).
    Gut; 2014 Sep; 63(9):1424-30. PubMed ID: 24146170
    [Abstract] [Full Text] [Related]

  • 27. Pediatric-onset inflammatory bowel disease poses risk for low bone mineral density at early adulthood.
    Guz-Mark A, Rinawi F, Egotubov O, Shimon I, Shamir R, Assa A.
    Dig Liver Dis; 2017 Jun; 49(6):639-642. PubMed ID: 28179094
    [Abstract] [Full Text] [Related]

  • 28. Efficacy and safety of medical therapy for low bone mineral density in patients with inflammatory bowel disease: a meta-analysis and systematic review.
    Melek J, Sakuraba A.
    Clin Gastroenterol Hepatol; 2014 Jan; 12(1):32-44.e5. PubMed ID: 23981521
    [Abstract] [Full Text] [Related]

  • 29. Nandrolone decanoate and intranasal calcitonin as therapy in established osteoporosis.
    Flicker L, Hopper JL, Larkins RG, Lichtenstein M, Buirski G, Wark JD.
    Osteoporos Int; 1997 Jan; 7(1):29-35. PubMed ID: 9102059
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of monthly ibandronate in men with low bone density.
    Orwoll ES, Binkley NC, Lewiecki EM, Gruntmanis U, Fries MA, Dasic G.
    Bone; 2010 Apr; 46(4):970-6. PubMed ID: 20060082
    [Abstract] [Full Text] [Related]

  • 31. Osteoporosis in inflammatory bowel disease: effect of calcium and vitamin D with or without fluoride.
    Abitbol V, Mary JY, Roux C, Soulé JC, Belaiche J, Dupas JL, Gendre JP, Lerebours E, Chaussade S, Groupe D'etudes Thérapeutiques des Affections Inflammatoires Digestives (GETAID).
    Aliment Pharmacol Ther; 2002 May; 16(5):919-27. PubMed ID: 11966500
    [Abstract] [Full Text] [Related]

  • 32. Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
    Bianchi ML, Colombo C, Assael BM, Dubini A, Lombardo M, Quattrucci S, Bella S, Collura M, Messore B, Raia V, Poli F, Bini R, Albanese CV, De Rose V, Costantini D, Romano G, Pustorino E, Magazzù G, Bertasi S, Lucidi V, Traverso G, Coruzzo A, Grzejdziak AD.
    Lancet Respir Med; 2013 Jul; 1(5):377-85. PubMed ID: 24429202
    [Abstract] [Full Text] [Related]

  • 33. Effect of supplementation of calcium and vitamin D on bone mineral density and bone mineral content in peri- and post-menopause women; a double-blind, randomized, controlled trial.
    Di Daniele N, Carbonelli MG, Candeloro N, Iacopino L, De Lorenzo A, Andreoli A.
    Pharmacol Res; 2004 Dec; 50(6):637-41. PubMed ID: 15501704
    [Abstract] [Full Text] [Related]

  • 34. A double-blind placebo-controlled study of intravenous clodronate for prevention of steroid-induced bone loss in inflammatory bowel disease.
    Abitbol V, Briot K, Roux C, Roy C, Seksik P, Charachon A, Bouhnik Y, Coffin B, Allez M, Lamarque D, Chaussade S.
    Clin Gastroenterol Hepatol; 2007 Oct; 5(10):1184-9. PubMed ID: 17683996
    [Abstract] [Full Text] [Related]

  • 35. Bone Mass Development from Childhood into Young Adulthood in Patients with Childhood-onset Inflammatory Bowel Disease.
    Sigurdsson GV, Schmidt S, Mellström D, Ohlsson C, Kindblom JM, Lorentzon M, Saalman R.
    Inflamm Bowel Dis; 2017 Dec; 23(12):2215-2226. PubMed ID: 29064856
    [Abstract] [Full Text] [Related]

  • 36. Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study.
    Flodin L, Sääf M, Cederholm T, Al-Ani AN, Ackermann PW, Samnegård E, Dalen N, Hedström M.
    Clin Interv Aging; 2014 Dec; 9():1043-50. PubMed ID: 25045257
    [Abstract] [Full Text] [Related]

  • 37. A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers.
    Trovas GP, Lyritis GP, Galanos A, Raptou P, Constantelou E.
    J Bone Miner Res; 2002 Mar; 17(3):521-7. PubMed ID: 11874243
    [Abstract] [Full Text] [Related]

  • 38. Vitamin D3 Supplementation Increases Spine Bone Mineral Density in Adolescents and Young Adults With Human Immunodeficiency Virus Infection Being Treated With Tenofovir Disoproxil Fumarate: A Randomized, Placebo-Controlled Trial.
    Havens PL, Stephensen CB, Van Loan MD, Schuster GU, Woodhouse LR, Flynn PM, Gordon CM, Pan CG, Rutledge B, Harris DR, Price G, Baker A, Meyer WA, Wilson CM, Hazra R, Kapogiannis BG, Mulligan K, Adolescent Medicine Trials Network for HIV/AIDS Interventions (ATN) 109 Study Team.
    Clin Infect Dis; 2018 Jan 06; 66(2):220-228. PubMed ID: 29020329
    [Abstract] [Full Text] [Related]

  • 39. Calcium Plus Vitamin D Supplementation During the Third Trimester of Pregnancy in Adolescents Accustomed to Low Calcium Diets Does Not Affect Infant Bone Mass at Early Lactation in a Randomized Controlled Trial.
    Diogenes ME, Bezerra FF, Rezende EP, Donangelo CM.
    J Nutr; 2015 Jul 06; 145(7):1515-23. PubMed ID: 26019245
    [Abstract] [Full Text] [Related]

  • 40. Bone mineral density in spanish children at the diagnosis of inflammatory bowel disease.
    Masip E, Donat E, Polo Miquel B, Ribes-Koninckx C.
    Arch Osteoporos; 2021 Jun 19; 16(1):96. PubMed ID: 34145515
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.